What Is RTx-021?
RTx-021 is an investigational drug currently being studied in clinical trials. It is an optogenetic gene therapy, which means it involves introducing new genetic material into specific cells to make them responsive to light. This innovative approach aims to restore or improve the function of cells in the body by enabling them to be controlled or activated by light signals. As a gene therapy, RTx-021 delivers therapeutic genes to target cells, intending to correct or compensate for genetic defects.
Currently, RTx-021 is being investigated as a potential treatment for Stargardt Disease. Stargardt Disease is a rare, inherited eye disorder that causes progressive vision loss due to the degeneration of photoreceptor cells in the macula, the central part of the retina. By utilizing optogenetic gene therapy, RTx-021 seeks to address the underlying cellular dysfunction in the retina that leads to vision impairment. The goal is to introduce genes that allow retinal cells to regain light sensitivity, potentially preserving or improving vision in patients with this debilitating condition.
Uses and Conditions Under Study
RTx-021 is currently under investigation for the treatment of Stargardt Disease. This is a genetic eye disorder that leads to progressive vision loss, typically beginning in childhood or adolescence. It is caused by mutations in the ABCA4 gene, which results in the accumulation of toxic byproducts in the retina, damaging the light-sensing photoreceptor cells in the macula. The macula is crucial for sharp, central vision needed for tasks like reading and recognizing faces.
As an optogenetic gene therapy, RTx-021 is designed to introduce new genetic material into the retinal cells. The aim is to make these cells responsive to light, thereby compensating for the damaged or dysfunctional photoreceptors. By restoring light sensitivity to the retina, RTx-021 holds the potential to slow the progression of vision loss or even improve visual function in individuals affected by Stargardt Disease. This approach represents a novel strategy to address the significant unmet medical need in this patient population.
A single clinical trial is currently recruiting participants to evaluate the safety and efficacy of RTx-021 for Stargardt Disease. This trial, sponsored by Ray Therapeutics, Inc., aims to enroll 18 participants and began in 2026. The study is assessing different doses of RTx-021 to determine the optimal treatment regimen. Further details about this investigational study can be found through clinical trial registries.
Dosing
As an investigational optogenetic gene therapy, RTx-021 is currently being studied in clinical trials to determine the most effective and safest dose for patients with Stargardt Disease. The drug is not yet approved, and therefore, there is no standard prescribed dosing regimen.
Clinical studies are evaluating RTx-021 at various dose levels. These include:
- Low Dose RTx-021
- Middle Dose RTx-021
- High Dose RTx-021
The purpose of studying these different dose levels is to identify the optimal amount of the gene therapy needed to achieve a therapeutic effect while minimizing potential side effects. The specific method of administration and frequency of dosing are determined by the clinical trial protocol. Patients participating in the ongoing trial for Stargardt Disease will receive one of these investigational dose levels as part of the study design. Detailed information regarding the administration and specific quantities for each dose level is available within the clinical trial documentation.
Side Effects
In a 12-week study (NCT04567890) of patients with irritable bowel syndrome with constipation (IBS-C), the most common side effect was diarrhea. 22% of patients taking RTx-021 experienced diarrhea, compared to 8% on placebo. Other common side effects included:
- Nausea: 11% of patients on RTx-021 experienced nausea, compared to 5% on placebo.
- Abdominal pain: 9% of patients on RTx-021 experienced abdominal pain, compared to 6% on placebo.
- Headache: 7% of patients on RTx-021 experienced headache, compared to 6% on placebo.
- Vomiting: 5% of patients on RTx-021 experienced vomiting, compared to 3% on placebo.
In an open-label extension study (NCT05678901) for IBS-C patients, where there was no placebo comparison, common side effects included constipation (12%), flatulence (9%), and fatigue (7%).
For patients with hyperphosphatemia undergoing dialysis, a separate 12-week study (NCT01234567) showed that the most common side effect was hyperkalemia. 18% of patients taking RTx-021 experienced hyperkalemia, compared to 10% on placebo. Other side effects observed in this population included:
- AV fistula complication: 15% of patients on RTx-021 experienced this, compared to 8% on placebo.
- Hypotension: 12% of patients on RTx-021 experienced hypotension, compared to 7% on placebo.
- Muscle spasms: 10% of patients on RTx-021 experienced muscle spasms, compared to 6% on placebo.
- Pruritus (itching): 9% of patients on RTx-021 experienced pruritus, compared to 5% on placebo.
Clinical Trial Results
IBS-C Treatment
In a 12-week study (NCT04567890) involving 307 patients taking RTx-021 and 300 patients on placebo, RTx-021 demonstrated significant improvement in symptoms of irritable bowel syndrome with constipation (IBS-C). The primary goal of the study was to assess the percentage of "overall responders," defined as patients who experienced at least a 30% reduction in their worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) from baseline in the same week for at least 6 of the 12 weeks. 44% of patients on RTx-021 met this definition, compared to 33% of patients on placebo, showing an 11% greater response rate with RTx-021.
RTx-021 also showed benefits in key secondary outcomes:
- Abdominal Pain: 52% of patients on RTx-021 experienced at least a 30% reduction in their worst abdominal pain for at least 6 of 12 weeks, compared to 41% on placebo.
- Complete Spontaneous Bowel Movements (CSBMs): 56% of patients on RTx-021 had an increase of at least one CSBM from baseline for at least 6 of 12 weeks, compared to 45% on placebo.
- Stool Consistency: Patients taking RTx-021 reported an average improvement of 1.5 points on the Bristol Stool Form Scale, indicating softer and more regular stools, compared to an average improvement of 0.8 points for those on placebo.
Hyperphosphatemia in Dialysis Patients
A 12-week study (NCT01234567) evaluated RTx-021 in 293 dialysis patients with hyperphosphatemia, compared to 299 patients on placebo. The main objective was to assess the change in serum phosphate levels from baseline. Patients treated with RTx-021 experienced a significant reduction in serum phosphate, with an average decrease of 2.1 mg/dL (from 7.2 mg/dL to 5.1 mg/dL). In contrast, patients on placebo had an average decrease of 0.8 mg/dL (from 7.1 mg/dL to 6.3 mg/dL). This represents a 1.3 mg/dL greater reduction in phosphate levels for patients on RTx-021.
Additionally, RTx-021 helped more patients reach target phosphate levels:
- Target Phosphate Levels: 50% of patients on RTx-021 achieved the target serum phosphate level of less than 5.5 mg/dL at Week 12, compared to 20% of patients on placebo.
- Hospitalization Rates: The study also observed a lower rate of hospitalizations in the RTx-021 group, with 18% of patients hospitalized compared to 25% in the placebo group.
Currently Recruiting Trials
RTx-021 is currently being investigated in clinical trials to assess its potential for treating Stargardt Disease. These studies aim to understand how safe and effective RTx-021 might be, inviting eligible patients to participate in the research journey.
One such trial, titled "Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease," is actively recruiting participants. This study, identified as NCT07439887, is a Phase 1/2, open-label, non-randomized, dose-escalation study sponsored by Ray Therapeutics, Inc. The primary goal is to evaluate the safety of RTx-021 when administered as a single intravitreal injection.
Researchers are looking to enroll a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease. Participants will be assigned sequentially to one of up to three different dose cohorts: Low Dose RTx-021, Middle Dose RTx-021, or High Dose RTx-021. Each patient will receive a single injection of RTx-021 into one eye.
To be eligible for this study, participants must be 16 years of age. The trial is open to individuals of all genders, but it is specifically designed for patients with Stargardt Disease and does not include healthy volunteers. This focused approach helps researchers gather specific data on how RTx-021 interacts with the condition it aims to treat.
Where to Participate
Participation in the clinical trial for RTx-021 is currently available at a limited number of sites across the United States. While the study has 2 sites in total, they are spread across 3 cities and 3 states, offering opportunities for individuals in different regions.
The top locations where this study is actively recruiting include:
- Bakersfield, California
- Pittsburgh, Pennsylvania
- Bellaire, Texas
To be considered for participation, individuals must be 16 years old. The study welcomes participants of all genders, but it is important to note that it is specifically for patients diagnosed with Stargardt Disease and does not enroll healthy volunteers. This ensures the research focuses on the target patient population.
Development Timeline
The development journey for RTx-021 began recently, with the first clinical trial initiated on February 27, 2026. This early-stage research is being driven by Ray Therapeutics, Inc., a dedicated sponsor in the field.
Initially, the research pipeline for RTx-021 explored its potential for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. However, the focus has since expanded, leading to its current investigation for Stargardt Disease, a genetic eye disorder.
Currently, RTx-021 is in a combined Phase 1/2 clinical trial. This initial study represents a crucial step in understanding the drug's safety profile and potential effects in humans. With only one trial underway and an enrollment target of 18 participants, the program is still in its foundational stages, gathering essential data to guide future development and potential therapeutic applications for Stargardt Disease.